compil event come
soon biotech coverag
follow highlight
note highlight event catalyst biotechnolog coverag anticip
soon well highlight week
pdufa date oral film candid sympazan aka clobazam oral film
low risk event aqst demonstr bio-equival model probabl
success sympazan sympazan contribut roughli fourth price target
aqst plan submit two nda year liberv buccal film diazepam oral film
result oloranib crohn diseas pain sometim quarter
made call event given rel uncharacter target set oloranib
valuat arena time
abdomin pain efficaci result expect subject posit revisit model
could point potenti broadli pain agent
argenx se argx butler mo pt risk-adjust dcf-deriv expect top-lin result
phase efgartigimod itp septemb mg/kg vs placebo three week weekli
dose subject see preview note
bolster posit phase result efgartigimod myasthenia gravi mg pemphigu
vulgari pv also driven autoantibodi anticip phase itp prove posit
believ success trial measur demonstr improv increas platelet
count importantli reduct autoantibodi correl clinic benefit also
expect see respond analys platelet count increas includ increas baselin
relev clinic threshold
assign probabl success itp program increas late june
back posit phase result pv
relev mechan valid posit result itp relat
anti-fcrn molecul ucb rozanolixizumab reduct total igg
patient consid respond platelet count platelet baselin
cytokinet butler mo pt risk-adjust dcf-deriv expect result two mid-
stage trial skelet muscl activ reldesemtiv quarter
despit delay fortitude- phase trial reldesemtiv al conduct
partner astella nc phase result copd phase interim frailti reldesemtiv
expect quarter
earn note updates/detail
report read conjunct import disclosur inform includ attest regul analyst certif
bempedo acid ba ezetimib fixed-dos combin fdc phase trial august
highli confid posit result placebo-adjust ldl-c lower note
patient background high-dos statin
assign probabl success ba program
late septemb expect phase result subject treat ba monotherapi
studi also highli confid posit result placebo-adjust ldl-c
lower continu good safety/toler
bayko mp risk-adjust dcf-deriv sept pdufa data ali treat
follow fda antimicrobi drug advisori committe meet held august assign
probabl success
phase data patient sept intern symposium retin
data import valu infect point prqr opinion provid
first look efficaci lookout restoration/improv visual
function retin structur
week recap
coverag follow compani ipo see note
last month ipo rais net aquest provid fund least month
compani appli differenti pharmfilm oral deliveri technolog found
suboxon film improv outcom complianc import set epilepsi near-
mid-term catalyst includ august pdufa date clobazam keep
investor engag name
nc exercis option global exclus right anti-garp simpl antibodi
see note
treg target io compani first partner develop april
argenx receiv mileston total develop
regulatori commerci mileston avail plu tier royalti product sale expect
potenti entri clinic late
dbv technolog dbvt bayko mo pt risk-adjust dcf-deriv regulatori
commerci matter top mind jmp-host investor meet dbvt new see
note
dbvt prepar submit bla viaskin peanut octob look accept
file day later first posit mileston dbvt could meaning de-
risk event think support upward momentum stock also detail fda
interact launch prepared commerci strategi pipelin develop
yearexpect open label eyebrow regrowth result phase ii studi stem-cel mobil allogen pivot open-label single-arm phase ii trial avapritinib advanc sm oral film clobazam pdufa result ba ezetimib fixed-dos combin fdc trial prqrphase lca data top-lin result efgartigimod data ali treat ntm septemberesprphas result subject treat bempedo acid monotherapi studi top-lin data phase iia trial eosinophil result oloranib crohn diseas data first cohort liquid acut interim analysi pacritinib phase ii myelofibrosi opinion pacritinib result reldesemtiv copd astella interim result reldesemtiv elderli phase trial eryaspas pancreat phase trial erymethionas solid tumor data single-dos portion phase hv atop derm patient acn ad pk/pd data phase trial entinostat/aromasin bc cohort data nationwid microdystrophin program world muscl societi phase pemigatinib formerli cholangiocarcinoma bladder cancer date oliceridin acut date larotrectinib nda ntrk-fusion cancer full data efgartigimod itp argxphas full data aml phase ctcl pdufa studi add-on therapi three-month data pnh patient receiv open-label phase second group first studi submiss tenapanor data phase tripl combo hair regrowth phase ii combin datat nda top-line result data phase iia studi alopecia data phase ii trial eryaspas result ascend trial mglur result cbd oral solut childhood absenc chronic cough resultselli
yearexpect result magnolia phase trial ganaxolon sever result amarylli trial ganaxolon moder result five day treatment ganaxolon refractori statu epilepticu result epilept encephalopathi includ dravet syndrom lennox-gastaut file decis top-line data tnbc encor mad trial data cancer pt phase ii develop strategi data phase ii studi aml first-lin combin data phase ii studi r/r aml md combin data phase dose escal advanc solid tumor patient result nuplazid trial palisad rams data trial children age ii ahu proof-of-concept data phase i/ii cohort data lumasiran ole initi phase ii trial initi phase ii trial interim result efgartigimod interim result subcutan efgartigimod chronic autoimmun time nda submiss rest-on phase result phase iia combat studi combo keytruda pancreat initi lead-in period genesi phase scm autolog transplant result phase ib/ii studi combo tecentriq updat data on-going phase trial avapritinib gist updat data phase trial avapritinib advanc sm preclin data fibrodysplasia ossifican progressiva least addit discoveri new pipelin combin data rcc phase ii combin data phase ii cantata studi combin cabozantinib pacritinib interim result registr path enrol second pivot studi line data phase dose escal solid hematolog data phase expans solid tumor driven kit phase ib rebastinib combo trial i/o chemotherapi phase ii trial eryaspas pancreat triplex data sot phase ii data allogen nda full data jakafi acut phase result lumateperon monotherapi bipolar depress studi phase result luateperon dementia-associ result multiple-rising-dos phase trial adjunct mild-to-moder phase iib top-lin data sadal r/r aa selinexor r/r mm base storm result aprilaki biotechnolog
yearexpect result magnolia phase trial ganaxolon sever result amarylli trial ganaxolon moder result five day treatment ganaxolon refractori statu epilepticu result epilept encephalopathi includ dravet syndrom lennox-gastaut file decis top-line data tnbc encor mad trial data cancer pt phase ii develop strategi data phase ii studi aml first-lin combin data phase ii studi r/r aml md combin data phase dose escal advanc solid tumor patient result nuplazid phase dose-escal updat on-going phase ii trial tipifarnib hra mutant clinic data tipifarnib hematolog registr trial tipifarnib hra mutant hnscc poc studi tipifarnib hra mutant squamou non-smal cell lung cancer phase i/ii clinic data patient acquir resist phase clinic trial patient acquir resist updat larotrectinib trk fusion clinic submit european complet phase head-to-head studi tremfya vs cosentyx glaucoma data phase trial phase data movement interim data cohort interim data cohort data phase mg inarigivir co-administ data monotherapi combin expans cohort r/r ovarian cancer carboplatin hr breast cancer next develop result hetlioz smith-mageni result tradipit approv decis teza/iva studi ole cohort mg phase achiev trial end pivot phase ii trial avapritinib indol smolder sm end merger end merger end complet re-examin process ind submissionaprilaki biotechnolog
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign liisa bayko jason butler donald elli konstantino
 aprilaki roy buchanan nazibur rahman jonathan wolleben
jmp secur current make market secur arbutu biopharma corp acadia pharmaceut inc achillion
inc trevena inc inc incorpor
jmp secur receiv compens bank servic render novan inc spring bank pharmaceut inc
past month
jmp secur manag co-manag public offer secur inc aquest therapeut inc
inc morphosi ag marinu pharmaceut inc summit plc syro pharmaceut inc vanda
smmt past month receiv compens
jmp secur expect receiv intend seek compens invest bank servic arbutu biopharma corp
inc inc inc trevena inc inc
next month
issuer number underwrit includ jmp secur among other defend class action lawsuit issuer
indemnifi underwrit connect therewith pursuant term applic underwrit agreement
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic august
co
servic
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
order obtain stock price chart addit applic disclosur inform concern jmp recommend
